Table 2 Patient- and tumor characteristics in relation to post-treatment tissue cholesterol

Age years (median)

63.0

67.5

0.97

Tumor size mm (median)

22.5

20.5

0.47

Tumor grade (NHG)

0.26

 1

7

2

 2

12

5

 3

9

7

Mitotic index

0.10

 1

17

5

 2

4

1

 3

7

7

ER (n = 31)

0.31

 Positive

21

7

 Negative

1

2

PR (n = 31)

0.14

 Positive

19

6

 Negative

3

3

HER2 (n = 30)

0.97

 0

5

2

 1+

7

3

 2+

5

3

 3+

4

1

Ki67 index (n = 26)

0.02*

 Low

14

1

 High

5

6

HMGCR (n = 38)

0.87

 Negative

10

4

 Positive

16

8

Serum lipid levels, median (n = 42)

 LDL pre-treatment

3.76

3.21

0.20

 HDL pre-treatment

1.60

1.41

0.54

 Cholesterol pre-treatment

6.10

5.20

0.08

 Apoliporotein B pre-treatment

1.07

0.91

0.11

 Apolipoprotein A1 pre-treatment

1.65

1.72

0.84

 LDL post-treatment

1.76

1.66

0.73

 HDL post-treatment

1.58

1.51

0.56

 Cholesterol post-treatment

3.70

3.45

0.47

 Apolipoprotein B post-treatment

0.60

0.55

0.38

 Apolipoprotein A1 post-treatment

1.58

1.51

0.45